Products Elranatamab + Daratumumab + Lenalidomide
Elranatamab + Daratumumab + Lenalidomide Phase 2 Recruiting ⚡ Active Multiple Myeloma, Newly Diagnosed
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Aug 8, 2025 → Apr 1, 2033
About Elranatamab + Daratumumab + Lenalidomide Elranatamab + Daratumumab + Lenalidomide is a phase 2 stage product being developed by Pfizer for Multiple Myeloma, Newly Diagnosed. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06974786. Target conditions include Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM).
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT06974786 Phase 2 Recruiting Aug 8, 2025 Apr 1, 2033 Multiple Myeloma, Newly Diagnosed
Competing Products 20 competing products in Multiple Myeloma, Newly Diagnosed
See all competitors Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Pfizer